SCHEMBL158333

SCHEMBL158333

CC(N)c1cccc(Cl)c1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 2/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
NFKB1 P19838 1/20 1.00
LMNA P02545 2/20 0.96
ALDH1A1 P00352 1/20 0.96
GLA P06280 1/20 0.96
TP53 P04637 1/20 0.47
HTT P42858 1/20 0.47
IDO1 P14902 1/20 0.46
TDO2 P48775 1/20 0.46
TSHR P16473 1/20 0.39
PDCD1LG2 Q9BQ51 3/20 0.39
CD274 Q9NZQ7 3/20 0.39
CFD P00746 1/20 0.39
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
KCNH2 Q12809 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8207165 1.00 PNMT (1.00) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL8207792 1.00 PNMT (1.00) PNMTCYP1A2CYP3A4CYP2D6NFKB1
Hydrochloric Acid SCHEMBL1321451 0.98 LMNA (1.00) PNMTCYP1A2CYP3A4CYP2D6NFKB1
Methylamine SCHEMBL6500291 0.82 PNMT (0.69) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL29668896 0.81 CYP3A4 (0.68) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL423182 0.81 CYP1A2 (0.68) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL22801396 0.81 CYP1A2 (0.68) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL703283 0.81 CYP3A4 (0.68) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL9985739 0.81 CYP3A4 (0.68) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL4706452 0.81 CYP3A4 (0.68) PNMTCYP1A2CYP3A4CYP2D6NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 534 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4737898-A2 SEPARATION AND ISOLATION OF NUCLEIC ACIDS USING AFFINITY LIGANDS BOUND TO A SOLID SURFACE EMP Biotech GmbH (DE) 2026-05-06 EP claimed
EP-4592297-A1 AN ORGANIC BORON COMPOUND, AN ORGANIC LIGHT EMITTING DIODE COMPRISING THE ORGANIC BORON COMPOUND, A USE OF THE DIODE, AND A CONSUMER PRODUCT Noctiluca S.A. (PL) 2025-07-30 EP claimed
CN-114715861-B Synthesis method of linear macromolecule BN precursor 中国人民解放军国防科技大学 2023-07-28 CN claimed
WO-2023059810-A1 STENTS AND METHODS OF USE UNIVERSITY OF CONNECTICUT (US) 2023-04-13 WO claimed
WO-2023044463-A1 SILK FIBROIN DERIVED BRUSH-LIKE POLYMERS UNIVERSITY OF CONNECTICUT (US) 2023-03-23 WO claimed
CN-114715861-A Synthesis method of linear polymer BN precursor 中国人民解放军国防科技大学 2022-07-08 CN claimed
US-20100143322-A1 USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE PLT PATENT & LICENCE TRADING LTD., C/O THE B-NET (GB) 2010-06-10 US claimed
US-20050080260-A1 Preparation of prodrugs for selective drug delivery LUMINIDE 2005-04-14 US claimed
EP-0414730-B1 Chemical Compounds and pharmaceutical compositions capable of releasing a drug MILLS RANDELL L (US) 1999-12-15 EP claimed
EP-3129065-B1 TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS AKAMARA THERAPEUTICS INC (US) 2026-05-13 EP disclosed
US-20260124324-A1 PHOTOCLICK CHEMISTRY OF SILK FOR TEMPORARY UV TATTOOS TUFTS COLLEGE (US) 2026-05-07 US disclosed
EP-4737898-A2 SEPARATION AND ISOLATION OF NUCLEIC ACIDS USING AFFINITY LIGANDS BOUND TO A SOLID SURFACE EMP Biotech GmbH (DE) 2026-05-06 EP disclosed
EP-4734896-A2 BIOPOLYMER-BASED TYMPANOSTOMY TUBES WITH PROGRAMMABLE, TUNABLE, AND ON-DEMAND DEGRADATION Trustees Of Tufts College (US) 2026-05-06 EP disclosed
EP-4735018-A2 CENTRIFUGALLY-MOLDED ARTICLES AND METHODS Trustees Of Tufts College (US) 2026-05-06 EP disclosed
EP-0518939-A1 ANTIARRHYTHMIC AGENTS BTG INTERNATIONAL LIMITED (GB) 1992-12-23 EP disclosed
WO-1992020325-A1 ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY ENDOCON, INC. (US) 1992-11-26 WO disclosed
WO-1992017169-A1 USE OF DEPRENYL TO MAINTAIN, PREVENT LOSS, OR RECOVER NERVE CELL FUNCTION THE UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION (CA) 1992-10-15 WO disclosed
WO-1991013865-A1 ANTIARRHYTHMIC AGENTS ISIS INNOVATION LIMITED (GB) 1991-09-19 WO disclosed
EP-0414730-A1 LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS Mills, Randell L. (US) 1991-03-06 EP disclosed
WO-1989009833-A1 LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS MILLS RANDELL L (US) 1989-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080260-A1 Preparation of prodrugs for selective drug delivery APEH, PAH, ALAD PNMT 3347/4885CYP1A2 214/4885CYP3A4 84/4885
US-20260124324-A1 PHOTOCLICK CHEMISTRY OF SILK FOR TEMPORARY UV TATTOOS PTMS, ITK, MATK PNMT 2762/4885CYP1A2 1851/4885CYP3A4 1628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.